Network Version
Adomeglivant Data Sheet
| Product Name: | Adomeglivant |
 |
|---|---|---|
| CAS No.: | 1488363-78-5 | |
| Cat. No.: | HY-19904 | |
| MWt: | 555.63 | |
| Formula: | C32H36F3NO4 | |
| Purity : | >98% | |
| Solubility: | DMSO : ≥ 100 mg/mL (179.98 mM) | |
| Mechanisms: | Target: Metabolic Disease | |
| Biological Activity: | ||
|
Adomeglivant (LY2409021) is a potent, selective glucagon receptor (GluR) allosteric antagonist. Adomeglivant is widely used in the research for type 2 diabetes mellitus[1][2][3].
IC50 & Target: GluR[1][2]
In Vitro: Adomeglivant dose-dependently blocks glucagon-induced the raise levels of cAMP in HEK293-GluR cells[2]. Adomeglivant fails to block cAMP-elevating actions of adenosine[2]. Adomeglivant exhibits high selectivity for family B GPCRs, and specifically interacts with a conserved binding motif within the GluR, GLP-1R, and GIP-R[2]. In Vivo: Adomeglivant (5 mg/kg; i.p.) completely abolishes the hyperglycaemic action of CNO (clozapine-N-oxide) in Avpires-Cre+ mice. (CNO is a specific, pharmacologically inert agonist for hM3Dq-induced membrane depolarisation and increased the firing rate in hM3Dq-expressing arginine-vasopressin (AVP) neurons.)[3] |
||
1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com